**8**(112):1332-1338. DOI: 10.1161/ CIRCULATIONAHA.104.530303

[22] Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: Findings from the pediatric cardiomyopathy registry. Circulation. 2007;**2**(115): 773-781

[23] Tariq M. Importance of genetic evaluation and testing in pediatric cardiomyopathy. World Journal of Cardiology. 2014;**6**:1156

[24] Talreja DR, Edwards WD, Danielson GK, Schaff HV, Tajik AJ, Tazelaar HD, et al. Constrictive pericarditis in 26 patients with histologically Normal pericardial thickness. Circulation. 2003;**10**(108): 1852-1857. DOI: 10.1161/01. CIR.0000087606.18453.FD

[25] Garcia MJ. Constrictive pericarditis versus restrictive cardiomyopathy? Journal of the American College of Cardiology. 2016;**5**(67):2061-2076

[26] Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy. Circulation Research. 2017;**9**(121): 819-837. DOI: 10.1161/CIRCRESAHA. 117.310982

[27] Bloomfield GS, Barasa FA, Doll JA, Velazquez EJ. Heart failure in sub-Saharan Africa. Current Cardiology Reviews. 2013;**5**(9):157-173

[28] Webber SA, Lipshultz SE, Sleeper LA, Lu M, Wilkinson JD, Addonizio LJ, et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype. Circulation. 2012;**9**(126):1237-1244. DOI: 10.1161/CIRCULATIONAHA. 112.104638

*Cardiomyopathies in Children: Genetics, Pathomechanisms and Therapeutic Strategies DOI: http://dx.doi.org/10.5772/intechopen.109896*

[29] Ditaranto R, Caponetti AG, Ferrara V, Parisi V, Minnucci M, Chiti C, et al. Pediatric restrictive cardiomyopathies. Frontiers in Pediatrics. 2022;**1**(9):1684

[30] Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies. Circulation. 2006;**4**(113):1807-1816. DOI: 10.1161/CIRCULATIONAHA. 106.174287

[31] Jensen B, van der Wal AC, Moorman AFM, Christoffels VM. Excessive trabeculations in noncompaction do not have the embryonic identity. International Journal of Cardiology. 2017;**1**(227): 325-330

[32] Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: A position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal. 2007;**12**(29): 270-276. DOI: 10.1093/eurheartj/ehm342

[33] Jefferies JL, Wilkinson JD, Sleeper LA, Colan SD, Lu M, Pahl E, et al. Cardiomyopathy phenotypes and outcomes for children with left ventricular myocardial noncompaction: Results from the pediatric cardiomyopathy registry. Journal of Cardiac Failure. 2015;**11**(21):877-884

[34] Kang SL, Forsey J, Dudley D, Steward CG, Tsai-Goodman B. Clinical characteristics and outcomes of cardiomyopathy in Barth syndrome: The UK experience. Pediatric Cardiology. 2016;**1**(37):167-176

[35] Rigaud C, Lebre AS, Touraine R, Beaupain B, Ottolenghi C, Chabli A, et al. Natural history of Barth syndrome: A national cohort study of 22 patients. Orphanet Journal of Rare Diseases. 2013; **5**(8):1-13. DOI: 10.1186/1750-1172-8-70

[36] Beffagna G, Zorzi A, Pilichou K, Marra MP, Rigato I, Corrado D, et al. Arrhythmogenic cardiomyopathy. European Heart Journal. 2020;**12**(41): 4457-4462

[37] Corrado D, Basso C, Judge DP. Arrhythmogenic cardiomyopathy. Circulation Research. 2017;**9**(121): 784-802. DOI: 10.1161/ CIRCRESAHA.117.309345

[38] Tabib A, Loire R, Chalabreysse L, Meyronnet D, Miras A, Malicier D, et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with Arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation. 2003;**12**(108):3000-3005. DOI: 10.1161/01.CIR.0000108396. 65446.21

[39] Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D, et al. Left-dominant arrhythmogenic cardiomyopathy: An under-recognized clinical entity. Journal of the American College of Cardiology. 2008;**12**(52):2175-2187

[40] Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: Proposed modification of the task force criteria. European Heart Journal. 2010; **4**(31):806-814. DOI: 10.1093/eurheartj/ ehq025

[41] Etoom Y, Govindapillai S, Hamilton R, Manlhiot C, Yoo SJ, Farhan M, et al. Importance of CMR within the task force criteria for the diagnosis of ARVC in children and adolescents. Journal of the American College of Cardiology. 2015;**3**(65): 987-995

[42] te Riele ASJM, James CA, Sawant AC, Bhonsale A, Groeneweg JA, Mast TP, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy in the pediatric population. JACC: Clinical Electrophysiology. 2015;**12**(1):551-560

[43] Corrado D, Basso C, Thiene G. Is it time to include ion channel diseases among cardiomyopathies? Journal of Electrocardiology. 2005;**10**(38):81-87

[44] Dettmeyer RB, Kandolf R. Cardiomyopathies—Misdiagnosed as sudden infant death syndrome (SIDS). Forensic Science International. 2010; **1**(194):e21-e24

[45] Gopinathannair R, Etheridge SP, Marchlinski FE, Spinale FG, Lakkireddy D, Olshansky B. Arrhythmia-induced cardiomyopathies: Mechanisms, recognition, and management. Journal of the American College of Cardiology. 2015;**10**(66): 1714-1728

[46] Moore JP, Patel PA, Shannon KM, Albers EL, Salerno JC, Stein MA, et al. Predictors of myocardial recovery in pediatric tachycardia-induced cardiomyopathy. Heart Rhythm. 2014; **7**(11):1163-1169

[47] Kim JJ, Friedman RA, Eidem BW, Cannon BC, Arora G, Smith EO, et al. Ventricular function and Long-term pacing in children with congenital complete atrioventricular block. Journal of Cardiovascular Electrophysiology. 2007;**4**(18):373-377. DOI: 10.1111/ j.1540-8167.2006.00741.x

[48] Morimoto S. Sarcomeric proteins and inherited cardiomyopathies. Cardiovascular Research. 2007;**12**(77): 659-666. DOI: 10.1093/cvr/cvm084

[49] Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. New England Journal of Medicine. 2011; **4**(364):1643-1656. DOI: 10.1056/ NEJMra0902923

[50] Towbin JA. Inherited cardiomyopathies. Circulation Journal. 2014;**78**:2347-2356

[51] Bates MGD, Bourke JP, Giordano C, d'Amati G, Turnbull DM, Taylor RW. Cardiac involvement in mitochondrial DNA disease: Clinical spectrum, diagnosis, and management. European Heart Journal. 2012;**12**(33):3023-3033. DOI: 10.1093/eurheartj/ehs275

[52] Taylor MRG, Slavov D, Ku L, Lenarda AD, Sinagra G, Carniel E, et al. Prevalence of Desmin mutations in dilated cardiomyopathy. Circulation. 2007;**3**(115):1244-1251. DOI: 10.1161/ CIRCULATIONAHA.106.646778

[53] Kindel SJ, Miller EM, Gupta R, Cripe LH, Hinton RB, Spicer RL, et al. Pediatric cardiomyopathy: Importance of genetic and metabolic evaluation. Journal of Cardiac Failure. 2012;**5**(18): 396-403

[54] Fiorillo C, Astrea G, Savarese M, Cassandrini D, Brisca G, Trucco F, et al. MYH7-related myopathies: Clinical, histopathological and imaging findings in a cohort of Italian patients. Orphanet Journal of Rare Diseases. 2016;**7**(11): 1-14. DOI: 10.1186/s13023-016-0476-1

[55] Jhang WK, Choi JH, Lee BH, Kim GH, Yoo HW. Cardiac manifestations and associations with gene mutations in patients diagnosed with RASopathies. Pediatric Cardiology. 2016;**12**(37):1539-1547. DOI: 10.1007/ s00246-016-1468-6

[56] Kaski JP, Syrris P, Burch M, Tome-Esteban MT, Fenton M, Christiansen M, *Cardiomyopathies in Children: Genetics, Pathomechanisms and Therapeutic Strategies DOI: http://dx.doi.org/10.5772/intechopen.109896*

et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart. 2008;**7**(94): 1478-1484. DOI: 10.1136/ hrt.2007.134684

[57] Choudhry S, Puri K, Denfield SW. An update on pediatric cardiomyopathy. Current Treatment Options in Cardiovascular Medicine. 2019;**8**(21):36. DOI: 10.1007/s11936-019-0739-y

[58] Salman OF, El-Rayess HM, Khalil CA, Nemer G, Refaat MM. Inherited cardiomyopathies and the role of mutations in non-coding regions of the genome. Frontiers in Cardiovascular Medicine. 2018;**6**(5):77. DOI: 10.3389/ fcvm.2018.00077/full

[59] Purevjav E, Towbin JA. The Z-Disk Final Common Pathway in Cardiomyopathies. IntechOpen Book: Cardiomyopathy - Disease of the Heart Muscle; 2021

[60] McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. Journal of Clinical Investigation. 2013; **1**(123):19-26

[61] Florczyk-Soluch U, Polak K, Dulak J. The multifaceted view of heart problem in Duchenne muscular dystrophy. Cellular and Molecular Life Sciences: CMLS. 2021;**7**(78):5447-5468

[62] Jui E, Singampalli KL, Shani K, Ning Y, Connell JP, Birla RK, et al. The immune and inflammatory basis of acquired pediatric cardiac disease. Frontiers in Cardiovascular Medicine. 2021;**7**(8):812. DOI: 10.3389/ fcvm.2021.701224/full

[63] Norrish G, Elliott PM. Cardiomyopathies in children: Mitochondrial and storage disease. Progress in Pediatric Cardiology. 2018; **12**(51):16-23

[64] Sabbah HN. Barth syndrome cardiomyopathy: Targeting the mitochondria with elamipretide. Heart Failure Reviews. 2021;**3**(26):237-253. DOI: 10.1007/s10741-020-10031-3

[65] Neuwald AF. Barth syndrome may be due to an acyltransferase deficiency. Current Biology: CB. 1997;**8**(7):R462- R466

[66] Probst S, Oechslin E, Schuler P, Greutmann M, Boyé P, Knirsch W, et al. Sarcomere gene mutations in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype. Circulation: Cardiovascular. Genetics. 2011;**8**(4):367-374. DOI: 10.1161/CIRCGENETICS. 110.959270

[67] Miller EM, Hinton RB, Czosek R, Lorts A, Parrott A, Shikany AR, et al. Genetic testing in pediatric left ventricular noncompaction. Circulation: Cardiovascular. Genetics. 2017;**12**:10. DOI: 10.1161/CIRCGENETICS. 117.001735

[68] Postma AV, van Engelen K, van de Meerakker J, Rahman T, Probst S, Baars MJH, et al. Mutations in the sarcomere gene ¡i¿MYH7¡/i¿ in Ebstein anomaly. Circulation: Cardiovascular. Genetics. 2011;**2**(4):43-50. DOI: 10.1161/ CIRCGENETICS.110.957985

[69] Arndt AK, Schafer S, Drenckhahn JD, Sabeh MK, Plovie E, Caliebe A, et al. Fine mapping of the 1p36 deletion syndrome identifies mutation of PRDM16 as a cause of cardiomyopathy. The American Journal of Human Genetics. 2013;**7**(93):67-77

[70] Klaassen S, Kühnisch J, Schultze-Berndt A, Seidel F. Left ventricular

noncompaction in children: The role of genetics, morphology, and function for outcome. Journal of Cardiovascular Development and Disease. 2022;**6**(9):206

[71] Vatta M, Mohapatra B, Jimenez S, Sanchez X, Faulkner G, Perles Z, et al. Mutations in cypher/ZASPin patients with dilated cardiomyopathy and left ventricular non-compaction. Journal of the American College of Cardiology. 2003;**12**(42):2014-2027

[72] Camozzi D, Capanni C, Cenni V, Mattioli E, Columbaro M, Squarzoni S, et al. Diverse Lamin-dependent mechanisms interact to control chromatin dynamics. Nucleus. 2014; **9**(5):427-440. DOI: 10.4161/nucl.36289

[73] Kulikova O, Brodehl A, Kiseleva A, Myasnikov R, Meshkov A, Stanasiuk C, et al. The Desmin (DES) mutation p. A337P is associated with left-ventricular non-compaction cardiomyopathy. Genes. 2021;**1**(12):121

[74] Khan RS, Pahl E, Dellefave-Castillo L, Rychlik K, Ing A, Yap KL, et al. Genotype and cardiac outcomes in pediatric dilated cardiomyopathy. Journal of the American Heart Association. 2022;**1**(11):22854. DOI: 10.1161/JAHA.121.022854

[75] Hawley MH, Almontashiri N, Biesecker LG, Berger N, Chung WK, Garcia J, et al. An assessment of the role of vinculin loss of function variants in inherited cardiomyopathy. Human Mutation. 2020;**9**(41):1577-1587. DOI: 10.1002/humu.24061

[76] Toro R, Pérez-Serra A, Campuzano O, Moncayo-Arlandi J, Allegue C, Iglesias A, et al. Familial dilated cardiomyopathy caused by a novel frameshift in the BAG3 gene. PLoS One. 2016;**7**(11):e0158730. DOI: 10.1371/ journal.pone.0158730

[77] Ware SM, Wilkinson JD, Tariq M, Schubert JA, Sridhar A, Colan SD, et al. Genetic causes of cardiomyopathy in children: First results from the pediatric cardiomyopathy genes study. Journal of the American Heart Association. 2021; **5**(10):17731. DOI: 10.1161/ JAHA.120.017731

[78] Wu T, Liang Z, Zhang Z, Liu C, Zhang L, Gu Y, et al. PRDM16 is a compact myocardium-enriched transcription factor required to maintain compact myocardial Cardiomyocyte identity in left ventricle. Circulation. 2022;**2**(145):586-602. DOI: 10.1161/ CIRCULATIONAHA.121.056666

[79] Sarohi V, Srivastava S, Basak T. A comprehensive outlook on dilated cardiomyopathy (DCM): State-of-theart developments with special emphasis on OMICS-based approaches. Journal of Cardiovascular Development and Disease. 2022;**6**(9):174

[80] Pomiato E, Perrone MA, Palmieri R, Gagliardi MG. Pediatric myocarditis: What have we learnt so far? Journal of Cardiovascular Development and Disease. 2022;**5**(9):143

[81] Bowles NE, Ni J, Kearney DL, Pauschinger M, Schultheiss HP, McCarthy R, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. Journal of the American College of Cardiology. 2003;**8**(42): 466-472

[82] Sanna G, Serrau G, Bassareo PP, Neroni P, Fanos V, Marcialis MA. Children's heart and COVID-19: Up-todate evidence in the form of a systematic review. European Journal of Pediatrics. 2020;**7**(179):1079-1087. DOI: 10.1007/ s00431-020-03699-0

[83] Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity

*Cardiomyopathies in Children: Genetics, Pathomechanisms and Therapeutic Strategies DOI: http://dx.doi.org/10.5772/intechopen.109896*

in survivors of childhood cancer. Heart. 2007;**10**(94):525-533. DOI: 10.1136/ hrt.2007.136093

[84] Tunuguntla HP, Puri K, Denfield SW. Management of Advanced Heart Failure in children with cancer therapy-related cardiac dysfunction. Children. 2021;**9**(8):872

[85] Monda E, Rubino M, Lioncino M, Fraia FD, Pacileo R, Verrillo F, et al. Hypertrophic cardiomyopathy in children: Pathophysiology, diagnosis, and treatment of non-sarcomeric causes. Frontiers in Pediatrics. 2021;**2**(9):94

[86] Nguyen MB, Mital S, Mertens L, Jeewa A, Friedberg MK, Aguet J, et al. Pediatric hypertrophic cardiomyopathy: Exploring the genotype-phenotype association. Journal of the American Heart Association. 2022;**3**(11):24220. DOI: 10.1161/JAHA.121.024220

[87] Charron P. Danon's disease as a cause of hypertrophic cardiomyopathy: A systematic survey. Heart. 2004;**8**(90): 842-846. DOI: 10.1136/hrt.2003.029504

[88] Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology. 2011;**12**(50):v4-v12

[89] Cohen MI, Atkins MB. Arrhythmogenic right ventricular cardiomyopathy in the pediatric population. Current Opinion in Cardiology. 2022;**1**(37):99-108. DOI: 10.1097/HCO.0000000000000937

[90] McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). The Lancet. 2000; **6**(355):2119-2124

[91] van Lint FHM, Murray B, Tichnell C, Zwart R, Amat N, Deprez RHL, et al. Arrhythmogenic right ventricular cardiomyopathy-associated Desmosomal variants are rarely De novo. Circulation: Genomic and Precision Medicine. 2019; **8**(12):e002467. DOI: 10.1161/ CIRCGEN.119.002467

[92] Crocini C, Gotthardt M. Cardiac sarcomere mechanics in health and disease. Biophysical Reviews. 2021; **10**(13):637-652. DOI: 10.1007/ s12551-021-00840-7

[93] Westfall MV. Contribution of posttranslational phosphorylation to sarcomere-linked cardiomyopathy phenotypes. Frontiers in Physiology. 2016;**9**(7):407

[94] Solaro RJ. Multiplex kinase signaling modifies cardiac function at the level of Sarcomeric proteins. Journal of Biological Chemistry. 2008;**10**(283): 26829-26833

[95] Ladha FA, Thakar K, Pettinato AM, Legere N, Cohn R, Romano R, et al. Identifying cardiac actinin interactomes reveals sarcomere crosstalk with RNA-binding proteins. bioRxiv. 2020;**5**. DOI: 10.1101/2020.03.18.994004. Available from: https://www.biorxiv.org/ content/early/2020/05/05/2020.03. 18.994004. Eprint: https://www.biorxiv. org/content/early/2020/05/05/ 2020.03.18.994004.full.pdf

[96] Martin TG, Kirk JA. Under construction: The dynamic assembly, maintenance, and degradation of the cardiac sarcomere. Journal of Molecular and Cellular Cardiology. 2020;**11**(148): 89-102

[97] Kötter S, Krüger M. Protein quality control at the sarcomere: Titin protection and turnover and implications for

disease development. Frontiers in Physiology. 2022;**6**(13):1315

[98] Bers DM. Cardiac excitation– contraction coupling. Nature. 2002; **1**(415):198-205

[99] Schartner V, Laporte J, Böhm J. Abnormal excitation-contraction coupling and calcium homeostasis in myopathies and cardiomyopathies. Journal of Neuromuscular Diseases. 2019;**9**(6):289-305

[100] Nakano SJ, Walker JS, Walker LA, Li X, Du Y, Miyamoto SD, et al. Increased myocyte calcium sensitivity in end-stage pediatric dilated cardiomyopathy. American Journal of Physiology-Heart and Circulatory Physiology. 2019;**12**(317):H1221-H1230. DOI: 10.1152/ajpheart.00409.2019

[101] Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy:A paradigm for myocardial energy depletion. Trends in Genetics. 2003;**5**(19):263-268

[102] Erickson JR, He BJ, Grumbach IM, Anderson ME. CaMKII in the cardiovascular system: Sensing redox states. Physiological Reviews. 2011; **7**(91):889-915

[103] Hudmon A, Schulman H. Structurefunction of the multifunctional Ca2 +/calmodulin-dependent protein kinase II. The Biochemical Journal. 2002; **6**(364):593-611

[104] Cimiotti D, Fujita-Becker S, Möhner D, Smolina N, Budde H, Wies A, et al. Infantile restrictive cardiomyopathy: cTnI-R170G/W impair the interplay of sarcomeric proteins and the integrity of thin filaments. PLoS One. 2020;**3**(15):e0229227. DOI: 10.1371/ journal.pone.0229227

[105] Cheng Y, Regnier M. Cardiac troponin structure-function and the influence of hypertrophic cardiomyopathy associated mutations on modulation of contractility. Archives of Biochemistry and Biophysics. 2016; **7**(601):11-21

[106] Solís C, Solaro RJ. Novel insights into sarcomere regulatory systems control of cardiac thin filament activation. Journal of General Physiology. 2021;**7**:153

[107] Bollen IAE, van der Meulen M, de Goede K, Kuster DWD, Dalinghaus M, van der Velden J. Cardiomyocyte hypocontractility and reduced myofibril density in end-stage pediatric cardiomyopathy. Frontiers in Physiology. 2017;**12**(8):1103

[108] Zaklyazminskaya E, Mikhailov V, Bukaeva A, Kotlukova N, Povolotskaya I, Kaimonov V, et al. Low mutation rate in the TTN gene in paediatric patients with dilated cardiomyopathy – A pilot study. Scientific Reports. 2019;**12**(9): 16409

[109] Herman DS, Lam L, Taylor MRG, Wang L, Teekakirikul P, Christodoulou D, et al. Truncations of Titin causing dilated cardiomyopathy. New England Journal of Medicine. 2012; **2**(366):619-628. DOI: 10.1056/ nejmoa1110186

[110] LeWinter MM, Granzier H. Cardiac Titin. Circulation. 2010;**5**(121): 2137-2145. DOI: 10.1161/ CIRCULATIONAHA.109.860171

[111] Ujfalusi Z, Vera CD, Mijailovich SM, Svicevic M, Yu EC, Kawana M, et al. Dilated cardiomyopathy myosin mutants have reduced force-generating capacity. Journal of Biological Chemistry. 2018; **6**(293):9017-9029

*Cardiomyopathies in Children: Genetics, Pathomechanisms and Therapeutic Strategies DOI: http://dx.doi.org/10.5772/intechopen.109896*

[112] Toepfer CN, Wakimoto H, Garfinkel AC, McDonough B, Liao D, Jiang J, et al. Hypertrophic cardiomyopathy mutations in ¡i¿MYBPC3¡/i¿ dysregulate myosin. Science Translational Medicine. 2019;**1**: 11. DOI: 10.1126/scitranslmed.aat1199

[113] Kensler RW, Shaffer JF, Harris SP. Binding of the N-terminal fragment C0– C2 of cardiac MyBP-C to cardiac F-actin. Journal of Structural Biology. 2011; **4**(174):44-51

[114] Hassoun R, Budde H, Mannherz HG, Lódi M, Fujita-Becker S, Laser KT, et al. De novo missense mutations in TNNC1 and TNNI3 causing severe infantile cardiomyopathy affect myofilament structure and function and are modulated by troponin targeting agents. International Journal of Molecular Sciences. 2021;**9**(22):9625

[115] Napierski NC, Granger K, Langlais PR, Moran HR, Strom J, Touma K, et al. A Novel "Cut and Paste" Method for In Situ Replacement of cMyBP-C Reveals a New Role for cMyBP-C in the Regulation of Contractile Oscillations. Circulation Research. 2020 3;126:737-749. doi: 10.1161/CIRCRESAHA.119.315760.

[116] Harris SP. Making waves: A proposed new role for myosin-binding protein C in regulating oscillatory contractions in vertebrate striated muscle. Journal of General Physiology. 2021;**3**:153

[117] Despond EA, Dawson JF. Classifying cardiac actin mutations associated with hypertrophic cardiomyopathy. Frontiers in Physiology. 2018;**4**(9):405

[118] Ehler E. Actin-associated proteins and cardiomyopathy - the 'unknown' beyond troponin and tropomyosin.

Biophysical Reviews. 2018;**8**(10): 1121-1128. DOI: 10.1007/s12551-018- 0428-1

[119] Erdmann C, Hassoun R, Schmitt S, Kikuti C, Houdusse A, Mazur AJ, et al. Integration of cardiac actin mutants causing hypertrophic (p.A295S) and dilated cardiomyopathy (p.R312H and p. E361G) into cellular structures. Antioxidants. 2021;**7**(10):1082

[120] Budde H, Hassoun R, Tangos M, Zhazykbayeva S, Herwig M, Varatnitskaya M, et al. The interplay between s-glutathionylation and phosphorylation of cardiac troponin i and myosin binding protein c in endstage human failing hearts. Antioxidants. 2021;**7**(10):1134

[121] Rouyère C, Serrano T, Frémont S, Echard A. Oxidation and reduction of actin: Origin, impact in vitro and functional consequences in vivo. European Journal of Cell Biology. 2022; **6**(101):151249

[122] Loescher CM, Breitkreuz M, Li Y, Nickel A, Unger A, Dietl A, et al. Regulation of titin-based cardiac stiffness by unfolded domain oxidation (UnDOx). Proceedings of the National Academy of Sciences of the United States of America. 2020;**9**(117): 24545-24556. DOI: 10.1073/ pnas.2004900117

[123] Li X, Zhao D, Guo Z, Li T, Qili M, Xu B, et al. Overexpression of SerpinE2/ protease nexin-1 contribute to pathological cardiac fibrosis via increasing collagen deposition. Scientific Reports. 2016;**12**(6):37635

[124] Schirone L, Forte M, Palmerio S, Yee D, Nocella C, Angelini F, et al. A review of the molecular mechanisms underlying the development and progression of cardiac remodeling.

Oxidative Medicine and Cellular Longevity. 2017;**2017**:1-16

[125] Tian J, An X, Niu L. Myocardial fibrosis in congenital and pediatric heart disease. Experimental and Therapeutic Medicine. 2017;**5**(13):1660-1664. DOI: 10.3892/etm.2017.4224

[126] Patel MD, Mohan J, Schneider C, Bajpai G, Purevjav E, Canter CE, et al. Pediatric and adult dilated cardiomyopathy represent distinct pathological entities. JCI Insight. 2017;**7**:2

[127] Recla S, Schmidt D, Logeswaran T, Esmaeili A, Schranz D. Pediatric heart failure therapy: Why β1-receptor blocker, tissue ACE-I and mineralocorticoid-receptor-blocker? Translational Pediatrics. 2019;**4**(8): 127-127

[128] Cicenia M, Drago F. Arrhythmogenic cardiomyopathy: Diagnosis, evolution, risk stratification and pediatric population—Where are we? Journal of Cardiovascular Development and Disease. 2022;**3**(9):98

[129] Austin KM, Trembley MA, Chandler SF, Sanders SP, Saffitz JE, Abrams DJ, et al. Molecular mechanisms of arrhythmogenic cardiomyopathy. Nature Reviews Cardiology. 2019;**9**(16): 519-537

[130] Li D, Liu Y, Maruyama M, Zhu W, Chen H, Zhang W, et al. Restrictive loss of plakoglobin in cardiomyocytes leads to arrhythmogenic cardiomyopathy. Human Molecular Genetics. 2011;**12**(20): 4582-4596. DOI: 10.1093/hmg/ddr392

[131] Ward M, Iskratsch T. Mix and (mis-)match – The mechanosensing machinery in the changing environment of the developing, healthy adult and diseased heart. Biochimica et Biophysica Acta (BBA) - molecular Cell Research. 2020:**3**;1867:118436

[132] Wu Y, Cazorla O, Labeit D, Labeit S, Granzier H. Changes in Titin and collagen underlie diastolic stiffness diversity of cardiac muscle. Journal of Molecular and Cellular Cardiology. 2000;**12**(32):2151-2161

[133] Hamdani N, Herwig M, Linke WA. Tampering with springs: Phosphorylation of titin affecting the mechanical function of cardiomyocytes. Biophysical Reviews. 2017;**6**(9):225-237. DOI: 10.1007/s12551-017-0263-9

[134] Hamdani N, Paulus WJ. Myocardial Titin and collagen in cardiac diastolic dysfunction. Circulation. 2013;**7**(128): 5-8. DOI: 10.1161/CIRCULATIONAHA. 113.003437

[135] Bhupathi SS, Chalasani S, Rokey R. Stiff heart syndrome. Clinical Medicine & Research. 2011;**6**(9):92-99. DOI: 10.3121/cmr.2010.899

[136] Chung CS, Hutchinson KR, Methawasin M, Saripalli C, Smith JE, Hidalgo CG, et al. Shortening of the elastic tandem immunoglobulin segment of Titin leads to diastolic dysfunction. Circulation. 2013;**7**(128):19-28. DOI: 10.1161/ CIRCULATIONAHA.112.001268

[137] Garcia-Canadilla P, Cook AC, Mohun TJ, Oji O, Schlossarek S, Carrier L, et al. Myoarchitectural disarray of hypertrophic cardiomyopathy begins pre-birth. Journal of Anatomy. 2019;**11**(235): 962-976. DOI: 10.1111/joa.13058

[138] Kraft T, Montag J. Altered force generation and cell-to-cell contractile imbalance in hypertrophic cardiomyopathy. Pflügers Archiv - European Journal of Physiology. 2019; *Cardiomyopathies in Children: Genetics, Pathomechanisms and Therapeutic Strategies DOI: http://dx.doi.org/10.5772/intechopen.109896*

**5**(471):719-733. DOI: 10.1007/ s00424-019-02260-9

[139] Dirkx E, da Costa Martins PA, Windt LJD. Regulation of fetal gene expression in heart failure. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1832;**2013**(12):2414-2424

[140] Wang K, Lin ZQ, Long B, Li JH, Zhou J, Li PF. Cardiac hypertrophy is positively regulated by MicroRNA miR-23a. Journal of Biological Chemistry. 2012;**1**(287):589-599

[141] Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proceedings of the National Academy of Sciences. 2009; **7**(106):12103-12108. DOI: 10.1073/ pnas.0811371106

[142] Stauffer BL, Russell G, Nunley K, Miyamoto SD, Sucharov CC. miRNA expression in pediatric failing human heart. Journal of Molecular and Cellular Cardiology. 2013;**4**(57):43-46

[143] Yu J, Zeng C, Wang Y. Epigenetics in dilated cardiomyopathy. Current Opinion in Cardiology. 2019;**5**(34):260-269

[144] Marino BS, Lipkin PH, Newburger JW, Peacock G, Gerdes M, Gaynor JW, et al. Neurodevelopmental outcomes in children with congenital heart disease: Evaluation and management. Circulation. 2012;**8**(126): 1143-1172. DOI: 10.1161/ CIR.0b013e318265ee8a

[145] Burstein DS, Shamszad P, Dai D, Almond CS, Price JF, Lin KY, et al. Significant mortality, morbidity and resource utilization associated with advanced heart failure in congenital heart disease in children and young adults. American Heart Journal. 2019; **3**(209):9-19

[146] Dipchand AI. Current state of pediatric cardiac transplantation. Annals of Cardiothoracic Surgery. 2018;**1**(7):31-55

[147] Bagnall RD, Weintraub RG, Ingles J, Duflou J, Yeates L, Lam L, et al. A prospective study of sudden cardiac death among children and young adults. New England Journal of Medicine. 2016; **6**(374):2441-2452. DOI: 10.1056/ NEJMoa1510687

[148] Jortveit J, Eskedal L, Hirth A, Fomina T, Døhlen G, Hagemo P, et al. Sudden unexpected death in children with congenital heart defects. European Heart Journal. 2016;**2**(37):621-626. DOI: 10.1093/eurheartj/ehv478

[149] Imanaka-Yoshida K. Inflammation in myocardial disease: From myocarditis to dilated cardiomyopathy. Pathology International. 2020;**1**(70):1-11. DOI: 10.1111/pin.12868

[150] Towbin JA, Ballweg J, Johnson J. Left Ventricular Noncompaction Cardiomyopathy. In: Jefferies JL, Chang AC, Rossano JW, Shaddy RE, Towbin JA, editors. Heart Failure in the Child and Young Adult. Boston: Academic Press: Elsevier; 2018. pp. 269-290. Available from: https://www.sciencedirect.com/science/ article/pii/B978012802393800020X. ISBN: 978-0-12-802393-8. DOI: 10.1016/B978-0- 12-802393-8.00020-X

[151] Leya FS, Arab D, Joyal D, Shioura KM, Lewis BE, Steen LH, et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. Journal of the American College of Cardiology. 2005; **6**(45):1900-1902

[152] Woulfe KC, Siomos AK, Nguyen H, SooHoo M, Galambos C, Stauffer BL, et al. Fibrosis and fibrotic gene expression in pediatric and adult patients with idiopathic dilated cardiomyopathy. Journal of Cardiac Failure. 2017;**4**(23): 314-324

[153] Wittnich C, Belanger MP, Bandali KS. Newborn hearts are at greater 'metabolic risk' during global ischemia – Advantages of continuous coronary washout. Canadian Journal of Cardiology. 2007;**3**(23):195-200

[154] Lai L, Leone TC, Keller MP, Martin OJ, Broman AT, Nigro J, et al. Energy metabolic reprogramming in the hypertrophied and early stage failing heart. Circulation. Heart Failure. 2014; **11**(7):1022-1031. DOI: 10.1161/ CIRCHEARTFAILURE.114.001469

[155] Miyamoto SD, Stauffer BL, Nakano S, Sobus R, Nunley K, Nelson P, et al. Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy. European Heart Journal. 2014;**1**(35):33-41. DOI: 10.1093/ eurheartj/ehs229

[156] Pan B, Hu D, Sun H, Lv T, Xu W, Tian J. Pediatric diastolic heart failure: Clinical features description of 421 cases. Frontiers in Pediatrics. 2022; **5**(10):656

[157] Sadat-Ebrahimi SR, Aslanabadi N. Role of MicroRNAs in diagnosis, prognosis, and treatment of acute heart failure: Ambassadors from intracellular zone. Galen Medical Journal. 2020;**6**(9): e1818

[158] Miyamoto SD, Karimpour-Fard A, Peterson V, Auerbach SR, Stenmark KR, Stauffer BL, et al. Circulating microRNA as a biomarker for recovery in pediatric dilated cardiomyopathy. The Journal of Heart and Lung Transplantation. 2015; **5**(34):724-733

[159] Jiao M, You HZ, Yang XY, Yuan H, Li YL, Liu WX, et al. Circulating

microRNA signature for the diagnosis of childhood dilated cardiomyopathy. Scientific Reports. 2018;**12**(8):724

[160] Oh JH, Kim GB, Seok H. Implication of microRNA as a potential biomarker of myocarditis. Clinical and Experimental Pediatrics. 2022;**5**(65): 230-238

[161] Bales ND, Johnson NM, Judge DP, Murphy AM. Comprehensive versus targeted genetic testing in children with hypertrophic cardiomyopathy. Pediatric Cardiology. 2016;**6**(37):845-851. DOI: 10.1007/s00246-016-1358-y

[162] Lee TM, Hsu DT, Kantor P, Towbin JA, Ware SM, Colan SD, et al. Pediatric cardiomyopathies. Circulation Research. 2017;**9**(121):855-873. DOI: 10.1161/CIRCRESAHA.116.309386

[163] Al-Hassnan ZN, Almesned A, Tulbah S, Alakhfash A, Alhadeq F, Alruwaili N, et al. Categorized genetic analysis in childhood-onset cardiomyopathy. Circulation: Genomic and Precision Medicine. 2020;**10**(13): 504-514. DOI: 10.1161/CIRCGEN.120. 002969

[164] Haanschoten DM, Adiyaman A, 't Hart NA, Jager PL, Elvan A. Value of 3D mapping-guided endomyocardial biopsy in cardiac sarcoidosis. European Journal of Clinical Investigation. 2021;**4**(51): e13497. DOI: 10.1111/eci.13497

[165] Esposito A, Palmisano A, Antunes S, Maccabelli G, Colantoni C, Rancoita PMV, et al. Cardiac CT with delayed enhancement in the characterization of ventricular tachycardia structural substrate. JACC: Cardiovascular Imaging. 2016;**7**(9):822-832

[166] Zeppenfeld K. Ventricular Tachycardia Ablation in Nonischemic *Cardiomyopathies in Children: Genetics, Pathomechanisms and Therapeutic Strategies DOI: http://dx.doi.org/10.5772/intechopen.109896*

Cardiomyopathy. JACC: Clinical Electrophysiology. 2018 9;4:1123-1140.

[167] Kim KH, Park JC, Yoon HJ, Yoon NS, Hong YJ, Park HW, et al. Usefulness of aortic strain analysis by velocity vector imaging as a new echocardiographic measure of arterial stiffness. Journal of the American Society of Echocardiography. 2009; **12**(22):1382-1388

[168] Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography. 2005;**12**(18): 1440-1463

[169] Lee CK, Margossian R, Sleeper LA, Canter CE, Chen S, Tani LY, et al. Variability of M-mode versus twodimensional echocardiography measurements in children with dilated cardiomyopathy. Pediatric Cardiology. 2014;**4**(35):658-667. DOI: 10.1007/ s00246-013-0835-9

[170] Pettersen MD, Du W, Skeens ME, Humes RA. Regression equations for calculation of Z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: An echocardiographic study. Journal of the American Society of Echocardiography. 2008;**8**(21):922-934

[171] Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. Journal of the American Society of Echocardiography. 2009;**6**(22):709-714

[172] Dragulescu A, Mertens L, Friedberg MK. Interpretation of left ventricular diastolic dysfunction in children with cardiomyopathy by echocardiography: Problems and limitations. Circulation Cardiovascular Imaging. 2013;**3**(6):254-261

[173] Ezon DS, Maskatia SA, Sexson-Tejtel K, Dreyer WJ, Jeewa A, Denfield SW. Tissue Doppler imaging measures correlate poorly with left ventricular filling pressures in pediatric cardiomyopathy. Congenital Heart Disease. 2015;**9**(10):E203-E209. DOI: 10.1111/chd.12267

[174] Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2016 update. Circulation. 2016;**1**(133):e38-e48. DOI: 10.1161/CIR.0000000000000350

[175] Buechel EV, Kaiser T, Jackson C, Schmitz A, Kellenberger CJ. Normal right- and left ventricular volumes and myocardial mass in children measured by steady state free precession cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance. 2009;**12**(11):19. DOI: 10.1186/1532-429X-11-19

[176] Ziółkowska L, Petryka J, Boruc A, Kawalec W. Comparison of echocardiography with tissue Doppler imaging and magnetic resonance imaging with delayed enhancement in the assessment of children with hypertrophic cardiomyopathy. Archives of Medical Science. 2017;**2**:328-336. DOI: 10.5114/aoms.2016.60404

[177] Ryan TD, Madueme PC, Jefferies JL, Michelfelder EC, Towbin JA, Woo JG, et al. Utility of echocardiography in the

assessment of left ventricular diastolic function and restrictive physiology in children and young adults with restrictive cardiomyopathy: A comparative echocardiography-catheterization study. Pediatric Cardiology. 2017;**2**(38):381-389. DOI: 10.1007/s00246-016-1526-0

[178] Masarone D, Valente F, Rubino M, Vastarella R, Gravino R, Rea A, et al. Pediatric heart failure: A practical guide to diagnosis and management. Pediatrics & Neonatology. 2017;**8**(58):303-312

[179] Colan SD. Pediatric Cardiomyopathy - NORD (National Organization for Rare Disorders); 2019. Available from: https:// rarediseases.org/rare-diseases/pediatriccardiomyopathy/?filter=complete-report [Accessed: 24-11-2022]

[180] Loss KL, Shaddy RE, Kantor PF. Recent and upcoming drug therapies for pediatric heart failure. Frontiers in Pediatrics. 2021;**11**(9):1192

[181] Das BB, Moskowitz WB, Butler J. Current and future drug and device therapies for pediatric heart failure patients: Potential lessons from adult trials. Children. 2021;**4**(8):322

[182] Halliday B. Examining the Effects of Mitochondrial Oxidative Stress in DCM - Full Text View. 2022. Available from: ClinicalTrials.gov.

[183] Renno M. Oral Ifetroban in Subjects with Duchenne Muscular Dystrophy - Full Text View. 2017. Available from: ClinicalTrials.gov.

[184] Rossano J, Taylor M, Greenberg B. Gene Therapy for Male Patients with Danon Disease (DD) Using RP-A501; AAV9.LAMP2B - Full Text View. 2019. Available from: ClinicalTrials.gov.

[185] Altarabsheh SE, Dearani JA, Burkhart HM, Schaff HV, Deo SV, Eidem BW, et al. Outcome of septal Myectomy for obstructive hypertrophic cardiomyopathy in children and young adults. The Annals of Thoracic Surgery. 2013;**2**(95): 663-669

[186] Sreeram N, Emmel M, Giovanni JVD. Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children. Journal of the American College of Cardiology. 2011; **12**(58):2501-2510

[187] Emmel M, Sreeram N, deGiovanni JV, Brockmeier K. Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in childhood. Zeitschrift für Kardiologie. 2005;**10**(94):699-703. DOI: 10.1007/s00392-005-0282-6

[188] Liebregts M, Steggerda RC, Vriesendorp PA, van Velzen H, Schinkel AFL, Willems R, et al. Longterm outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in the young and the elderly. JACC: Cardiovascular Interventions. 2016;**3**(9):463-469

[189] Aghdami N. Intracoronary Transplantation of Bone Marrow Derived Mononuclear Cells in Pediatric Cardiomyopathy - Full Text View. 2017. Available from: Clinical Trials.gov.

[190] Srour S. New Horizons for the Treatment of Cardiomyopathy in Children - Full Text View. 2021. Available from: ClinicalTrials.gov.

[191] Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 2014; **7**(64):83-99

*Cardiomyopathies in Children: Genetics, Pathomechanisms and Therapeutic Strategies DOI: http://dx.doi.org/10.5772/intechopen.109896*

[192] Jefferies JL, Towbin JA. Dilated cardiomyopathy. The Lancet. 2010; **2**(375):752-762

[193] Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. The Lancet. 2017;**7**(390):400-414

[194] Deshpande S, Sparks JD, Alsoufi B. Pediatric heart transplantation: Year in review 2020. The Journal of Thoracic and Cardiovascular Surgery. 2021; **8**(162):418-421

[195] Giafaglione J, Morrison A, Gowda C, Gajarski R, Nandi D. Pediatric donor heart allocation in the United States, 2006-2017: Current patterns and potential for improvement. Pediatric Transplantation. 2020;**9**(24):e13743. DOI: 10.1111/petr.13743

[196] Khan AM, Green RS, Lytrivi ID, Sahulee R. Donor predictors of allograft utilization for pediatric heart transplantation. Transplant International. 2016;**12**(29):1269-1275. DOI: 10.1111/tri.12835

[197] Padilla LA, Rhodes L, Sorabella RA, Hurst DJ, Cleveland DC, Dabal RJ, et al. Attitudes toward xenotransplantation: A survey of parents and pediatric cardiac providers. Pediatric Transplantation. 2021;**3**:25. DOI: 10.1111/petr.13851

Section 6
